Crossmark

Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma

Crossref DOI link: https://doi.org/10.1007/s12325-021-01919-z

Published Online: 2021-11-25

Published Print: 2022-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Samineni, Divya https://orcid.org/0000-0001-6300-2044
Huang, Weize

Gibiansky, Leonid

Ding, Hao

Zhang, Rong

Li, Chunze

Sinha, Arijit

Rajwanshi, Richa

Humphrey, Kathryn

Bazeos, Alexandra

Salem, Ahmed Hamed

Miles, Dale
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02055820 at ClinicalTrials.gov

Documents that mention this clinical trial

Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma
https://doi.org/10.1136/jitc-2022-006113

Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma
https://doi.org/10.1007/s12325-021-01919-z
License Information

Text and Data Mining valid from 2021-11-25

Version of Record valid from 2021-11-25
More Information

Article History

Received: 5 July 2021

Accepted: 7 September 2021

First Online: 25 November 2021

Document is current

Any future updates will be listed below